707 related articles for article (PubMed ID: 19489652)
41. Risk of infections in rheumatoid arthritis patients switching from anti-TNF agents to rituximab, abatacept, or another anti-TNF agent, a retrospective administrative claims analysis.
Johnston SS; Turpcu A; Shi N; Fowler R; Chu BC; Alexander K
Semin Arthritis Rheum; 2013 Aug; 43(1):39-47. PubMed ID: 23453683
[TBL] [Abstract][Full Text] [Related]
42. [Proposal for biologic drugs therapy in rheumatoid arthritis].
Curković B; Babić-Naglić D; Morović-Vergles J; Anić B; Grazio S; Kaliterna DM; Hanih M; Novak S
Reumatizam; 2010; 57(1):29-35. PubMed ID: 20941938
[TBL] [Abstract][Full Text] [Related]
43. Rheumatoid arthritis: beyond tumor necrosis factor-alpha antagonists, B cell depletion, and T cell blockade.
Manadan AM; Block JA
Am J Ther; 2008; 15(1):53-8. PubMed ID: 18223354
[TBL] [Abstract][Full Text] [Related]
44. Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry.
Leffers HC; Ostergaard M; Glintborg B; Krogh NS; Foged H; Tarp U; Lorenzen T; Hansen A; Hansen MS; Jacobsen MS; Dreyer L; Hetland ML;
Ann Rheum Dis; 2011 Jul; 70(7):1216-22. PubMed ID: 21551512
[TBL] [Abstract][Full Text] [Related]
45. Use of biologics in rheumatoid arthritis: where are we going?
Pucino F; Harbus PT; Goldbach-Mansky R
Am J Health Syst Pharm; 2006 Sep; 63(18 Suppl 4):S19-41. PubMed ID: 16960244
[TBL] [Abstract][Full Text] [Related]
46. [Correlation between different clinical activity and anti CC-P (anti-cyclic citrullinated peptide antibodies) titres in rheumatoid arthritis treated with three different tumor necrosis factors TNF-alpha blockers].
Benucci M; Turchini S; Parrochi P; Boccaccini P; Manetti R; Cammelli E; Manfredi M
Recenti Prog Med; 2006 Mar; 97(3):134-9. PubMed ID: 16700418
[TBL] [Abstract][Full Text] [Related]
47. Assessing the cost-effectiveness of biologic agents for the management of moderate-to-severe rheumatoid arthritis in anti-TNF inadequate responders in Italy: a modelling approach.
Cimmino MA; Leardini G; Salaffi F; Intorcia M; Bellatreccia A; Dupont D; Beresniak A
Clin Exp Rheumatol; 2011; 29(4):633-41. PubMed ID: 21813056
[TBL] [Abstract][Full Text] [Related]
48. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
[TBL] [Abstract][Full Text] [Related]
49. ACR70-disease activity score remission achievement from switches between all the available biological agents in rheumatoid arthritis: a systematic review of the literature.
Alivernini S; Laria A; Gremese E; Zoli A; Ferraccioli G
Arthritis Res Ther; 2009; 11(6):R163. PubMed ID: 19886983
[TBL] [Abstract][Full Text] [Related]
50. Treatment of juvenile idiopathic arthritis in the biologic age.
Stoll ML; Cron RQ
Rheum Dis Clin North Am; 2013 Nov; 39(4):751-66. PubMed ID: 24182853
[TBL] [Abstract][Full Text] [Related]
51. Molecular differences in anticytokine therapies.
Calabrese LH
Clin Exp Rheumatol; 2003; 21(2):241-8. PubMed ID: 12747285
[TBL] [Abstract][Full Text] [Related]
52. Do we need new treatment that goes beyond tumor necrosis factor blockers for rheumatoid arthritis?
Voll RE; Kalden JR
Ann N Y Acad Sci; 2005 Jun; 1051():799-810. PubMed ID: 16127017
[TBL] [Abstract][Full Text] [Related]
53. Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis: Systematic review and meta-analysis.
Maneiro RJ; Salgado E; Carmona L; Gomez-Reino JJ
Semin Arthritis Rheum; 2013 Aug; 43(1):9-17. PubMed ID: 23290690
[TBL] [Abstract][Full Text] [Related]
54. [Indications and efficacy of biologics in inflammatory arthritis].
Combe B
Bull Acad Natl Med; 2012 Oct; 196(7):1279-92; discussion 1293. PubMed ID: 23815014
[TBL] [Abstract][Full Text] [Related]
55. Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis.
Quartuccio L; Fabris M; Salvin S; Atzeni F; Saracco M; Benucci M; Cimmino M; Morassi P; Masolini P; Pellerito R; Cutolo M; Puttini PS; De Vita S
Rheumatology (Oxford); 2009 Dec; 48(12):1557-9. PubMed ID: 19789202
[TBL] [Abstract][Full Text] [Related]
56. [Biologic therapy of rheumatoid arthritis].
Damjanov N; Vojinović J
Srp Arh Celok Lek; 2009; 137(3-4):205-10. PubMed ID: 19459571
[TBL] [Abstract][Full Text] [Related]
57. Rheumatoid arthritis: Biological therapy other than anti-TNF.
Rossi D; Modena V; Sciascia S; Roccatello D
Int Immunopharmacol; 2015 Aug; 27(2):185-8. PubMed ID: 25840282
[TBL] [Abstract][Full Text] [Related]
58. Biologics in Inflammatory and Immunomediated Arthritis.
Luchetti MM; Benfaremo D; Gabrielli A
Curr Pharm Biotechnol; 2017; 18(12):989-1007. PubMed ID: 29278210
[TBL] [Abstract][Full Text] [Related]
59. Biologic agents in rheumatoid arthritis: an update for managed care professionals.
Agarwal SK
J Manag Care Pharm; 2011; 17(9 Suppl B):S14-8. PubMed ID: 22073935
[TBL] [Abstract][Full Text] [Related]
60. MRP8/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis.
Choi IY; Gerlag DM; Herenius MJ; Thurlings RM; Wijbrandts CA; Foell D; Vogl T; Roth J; Tak PP; Holzinger D
Ann Rheum Dis; 2015 Mar; 74(3):499-505. PubMed ID: 24297376
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
